Mitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study.
Marcia S BroseDaniel A PrymaKate L NewboldPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)